CSL partners with Alentis Therapeutics in up to $1.6bn deal to co-develop lixudebart, a claudin-1-targeting antibody for fibrosis indications.
Oct 06, 2026
AllschwilManufacturing
Description
Alentis Therapeutics has entered into an exclusive global partnership with Australian biopharmaceutical company CSL for the co-development and co-commercialization of lixudebart, an investigational antibody targeting claudin-1. Under the agreement, CSL will lead a clinical program and assume financial responsibility for development, including the ongoing Phase II RENAL trial, a planned Phase III study in AAV-RPGN, and additional Phase II trials in FSGS and PSC. The deal provides Alentis with up to $1.6 billion in potential payments. Lixudebart represents the lead program from Alentis' proprietary claudin-1 platform, which the Basel-based biotech has developed around a protein involved in cell-cell barriers.
Company Information
Company
Alentis Therapeutics
Location
Allschwil, Basel-Landschaft, Switzerland
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
AllschwilManufacturing